Related Experiment Video
Updated: Oct 1, 2025
08:45
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
2.1K
Aplastic Anemia Treated with Eltrombopag during Pregnancy
Yuri Suminaga1, Yoshitsugu Chigusa1, Tadakazu Kondo2
1Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Case Reports in Obstetrics and Gynecology
|March 7, 2022
Summary
Eltrombopag, a thrombopoietin receptor agonist, offers a potential treatment for pregnant women with severe aplastic anemia refractory to other therapies. This case study shows favorable maternal and fetal outcomes when eltrombopag is used cautiously with close monitoring.
Area of Science:
- Hematology
- Obstetrics
- Pharmacology
Background:
- Aplastic anemia is a rare, life-threatening blood disorder.
- Pregnancy can exacerbate aplastic anemia, posing significant risks.
- Current treatments for aplastic anemia in pregnancy are limited to supportive care.
Observation:
- A pregnant woman with aplastic anemia refractory to immunosuppressive therapy received eltrombopag.
- Treatment was continued throughout pregnancy after careful risk-benefit assessment.
- The patient achieved a successful vaginal delivery at 38 weeks gestation.
Findings:
- Eltrombopag treatment prevented the progression of pancytopenia during pregnancy.
- The mother experienced an uneventful postpartum recovery.
- The neonate showed no adverse effects, including thrombocytosis.
Implications:
- Eltrombopag may be a viable option for select pregnant patients with refractory aplastic anemia.
- Careful maternal and fetal monitoring, including neonatal blood exams, is crucial.
- Further research is needed to establish the safety and efficacy of eltrombopag in pregnancy.
